Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

5323 Harry Hines Boulevard, Dallas TX 75390

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty includes many distinguished members, including six who have been awarded Nobel Prizes since 1985. The faculty of almost 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments.

The Harold C. Simmons Comprehensive Cancer Center is the only NCI-designated Comprehensive Cancer Center in North Texas and one of just 48 NCI-designated Comprehensive Cancer Centers in the nation. Simmons Cancer Center includes 13 major cancer care programs with more than 250 adult and pediatric clinical trials open and enrolling at any given time. Simmons Cancer Center is among only 30 U.S. cancer research centers to be designated by the NCI as a National Clinical Trials Network Lead Academic Participating Site and is one of 15 sites included in the NCI Early Drug Development Opportunity Program (EDDOP). In addition, the Center’s education and training programs support and develop the next generation of cancer researchers and clinicians.

Website: Harold C. Simmons Comprehensive Cancer Center

Contact:
Erin Williams, Associate Director CRO Administration
214-648-7097

Trials at this location:

HCRN-GU21-517

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)

Status: Open to Accrual
Read More

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

Status: Open to Accrual
Read More

HCRN-GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Status: Closed to Accrual
Read More